Purpose Preclinical data suggest a contribution of the immune system to chemotherapy
response. In this study, we investigated the prespecified hypothesis that the presence of a …

Background Tumour-infiltrating lymphocytes (TILs) are predictive for response to neoadjuvant
chemotherapy in triple-negative breast cancer (TNBC) and HER2-positive breast cancer, …

Gene or protein expression data are usually represented by metric or at least ordinal
variables. In order to translate a continuous variable into a clinical decision, it is necessary to …

Purpose Modulation of immunologic interactions in cancer tissue is a promising therapeutic
strategy. To investigate the immunogenicity of human epidermal growth factor receptor 2 (…

Background In metastatic breast cancer, nab-paclitaxel has been shown to significantly
increase progression-free survival compared with solvent-based paclitaxel. The GeparSepto (…

In order to explore the effect of neoadjuvant chemotherapy (NACT) on clinical mid-course
and pathological complete response (pCR) at surgery in different biological breast cancer …

Introduction We have recently described an increased lymphocytic infiltration rate in breast
carcinoma tissue is a significant response predictor for anthracycline/taxane-based …

Aims Antibodies targeting the checkpoint molecules programmed cell death 1 (PD-1) and its
ligand PD-L1 are emerging cancer therapeutics. We systematically investigated PD-1 and …

The androgen receptor (AR) has been shown to be of potential prognostic importance in
retrospective cohorts. We evaluated immunohistochemical AR expression on a tissue …

Histone deacetylase (HDAC) inhibitors are an emerging class of targeted cancer therapeutics,
and little is known about HDAC expression in gynecologic malignancies. Therefore, we …